You are here: Industry Insights > ARDS

News List

Santhera explores lonodelestat to treat ARDS in Covid-19 patients pharmaceutical-technology
April 30, 2020
Swiss-based Santhera Pharmaceuticals has partnered with Cold Spring Harbor Laboratory (CSHL) to explore the use of lonodelestat (POL6014) as a potential treatment for acute respiratory distress syndrome (ARDS) caused by Covid-19.
Shiv Nadar University develops molecule with potential to cure COVID-19 expresspharma
April 29, 2020
The molecule has the potential to be developed into a drug that can cure Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients, animal trials to begin soon as a prelude to human trials.
Santhera, CSHL to Investigate Lonodelestat in COVID-19-related ARDS contractpharma
April 28, 2020
Lonodelestat (POL6014), a potent inhibitor of human neutrophil elastase (hNE), has potential as a therapeutic intervention for COVID-19-related ARDS.
Roivant Doses First Patient in Gimsilumab Trial for COVID-19 Acute Respiratory Distress Syndrome Prevention americanpharmaceuticalreview
April 17, 2020
Roivant Sciences announced the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomized, double-blind, placebo-controlled ...
Roivant Doses First Patient in Pivotal BREATHE Clinical Trial Evaluating Gimsilumab in COVID-19 Patients for the Prevention and Treatment of Acute Respiratory Distress Syndrome prnewswire
April 16, 2020
Roivant Sciences announced that the first patient was dosed at Temple University Hospital in Philadelphia in an adaptive, randomized, double-blind, placebo-controlled ...
Leading BioSciences Drug May Help Critical COVID-19 Patients contractpharma
April 09, 2020
Investigational drug, LB1148, being considered to treat respiratory distress and organ dysfunction in critically ill COVID-19 patients.
Ampio Pharma to Study Ampion in COVID-19 Induced ARDS contractpharma
April 03, 2020
Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug.
Citius licences Novellus’ stem cell therapy for Covid-19-related ARDS pharmaceutical-technology
April 03, 2020
Citius Pharmaceuticals has entered an exclusive six-month option agreement to licence a stem cell therapy from Novellus to treat acute respiratory distress syndrome (ARDS) related to Covid-19 infection.
FibroGenesis Files Expanded Patent Coverage for Fibroblast Cell Therapy for COVID-19 ARDS americanpharmaceuticalreview
April 02, 2020
FibroGenesis announced the filing of United States Provisional Patent Number 63/002,134 titled, "Peptides and Adjuvants for Augmentation of Fibroblast Therapy for Coronavirus."
Citius, Novellus Ink COVID-19 Pact contractpharma
April 02, 2020
Citius to license novel stem-cell therapy for acute respiratory distress syndrome (ARDS) associated with COVID-19.

Previous page 1 2 3 4 5 6 7 Next page